Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Puerto Rico has seen significant growth in recent years.
Customer preferences: Patients in Puerto Rico suffering from rheumatic diseases have been increasingly seeking out advanced treatments to manage their symptoms. This has led to a rise in demand for biologic drugs, which are designed to target specific inflammatory pathways in the body. Patients are also showing a preference for drugs that have fewer side effects and can be administered less frequently.
Trends in the market: There has been a shift towards the use of biologic drugs in Puerto Rico, which has driven growth in the Anti-Rheumatic Drugs market. This trend is in line with global market trends, as biologic drugs have become increasingly popular worldwide due to their effectiveness in managing rheumatic diseases. In addition, there has been an increase in the availability of biosimilars, which are more affordable versions of biologic drugs. This has made these treatments more accessible to patients in Puerto Rico.
Local special circumstances: Puerto Rico has a high prevalence of rheumatic diseases, which has contributed to the growth of the Anti-Rheumatic Drugs market. The island has a population of approximately 3.2 million people, and it is estimated that over 300,000 people in Puerto Rico suffer from rheumatic diseases. This high prevalence has created a large market for Anti-Rheumatic Drugs.
Underlying macroeconomic factors: Puerto Rico's economy has been struggling in recent years, which has had an impact on the healthcare sector. The island has a high poverty rate, and many patients struggle to afford the cost of healthcare. This has created a need for more affordable treatments, such as biosimilars. In addition, the island has been hit by natural disasters, which has disrupted the healthcare system. This has led to a greater need for advanced treatments that can be administered less frequently, as patients may have difficulty accessing healthcare facilities.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
